Heidelberg Epignostix
Key Facts
| Invested since | 2024 |
| Based in | Baden-Württemberg |
About the company
Heidelberg Epignostix is a healthcare company whose mission is to transform cancer diagnostics through data science. The company has developed novel AI-based bioinformatics algorithms with utility in cancer classification for improved accuracy in cancer diagnosis, prognosis and therapy management. The lead product, the Heidelberg Brain Classifier, is currently available as a research-use-only resource. Heidelberg Epignostix is located in Heidelberg, Germany. For more information visit www.epignostix.com.
Do you want to
know more about this company?
Zum Artikel
Dr. Katharina Severin Senior Investment Manager
Dr. Katharina SeverinSenior Investment Manager
Heidelberg Epignostix in the news
Zum Artikel
DKFZ spin-off Epignostix raises €4.3m Seed round to commercialize diagnostic tumor classifier
More startups from Life Sciences
heartbeat ONE provides a streamlined patient management tool for health care facilities of all sizes. It offers intelligent evaluations of diagnostics and treatment methods. It supports the preparation, documentation and …
To the complete profileof heartbeat medical
smartbax is developing a new generation of antibiotics to address the increasing spread of multidrug-resistant bacteria. Their team of experts works on innovative solutions focusing on substances that simultaneously address …
To the complete profileof smartbax
PraxisEins is a state-supported practice network with the aim of solving the impending GP care vacuum. In order to avert the structural undersupply in large parts of the country, the …
To the complete profileof PraxisEins
Numaferm developed a platform technology for fast, scalable and cost-efficient production of peptides and proteins, with a focus on pepteins (PEPTides & protEINS) in the range of 30-500 amino acids. …
To the complete profileof NUMAFERM
Heidelberg Epignostix is a healthcare company whose mission is to transform cancer diagnostics through data science. The company has developed novel AI-based bioinformatics algorithms with utility in cancer classification for …
To the complete profileof Heidelberg Epignostix
Next-generation therapy for atrial fibrillation and other arrhythmias.
To the complete profileof Argá Medtech
GS Bavaria is the world‘s first supplier of nano- hard metal materials on industrial scale. Production is extremely cost-efficient, sustainable and comes with minimal energy consumption through our unique bioleaching …
To the complete profileof GS Bavaria
Exit
Provecs Medical develops novel products from its platform technology for cancer treatment by specific activation of the immune system. Exit since July 2015.
To the complete profileof Provecs Medical
OMEICOS Therapeutics develops a novel, first-in-class, small molecule drug addressing a new Mode of Action for the treatment and prevention of atrial fibrillation.
To the complete profileof OMEICOS
Exit
KINAXO supports pharmaceutical companies in the development of targeted drugs and predictive biomarkers for personalized healthcare. Exit since Feb. 2011. Purchaser: Evotec AG
To the complete profileof KINAXO
Phialogics is an innovative start-up in the field of autoimmune diseases. Founded in 2021 by a team of widely recognized experts in protein engineering and immunology, the company based in …
To the complete profileof Phialogics
Exit
Capical is the world leading company for contact-free ECG-measurement via capacitive electrodes. The main application areas are drivers state monitoring for the automotive industry and contact-free cardiac monitoring solutions for …
To the complete profileof Capical